1 / 5

Flaherty K et al.

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer. Flaherty K et al. American Society of Clinical Oncology 2009; Abstract 9000. (Clinical Science Symposium Presentation). Introduction. V600E BRAF kinase activating mutation

sforbes
Download Presentation

Flaherty K et al.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical Oncology 2009; Abstract 9000. (Clinical Science Symposium Presentation)

  2. Introduction • V600E BRAF kinase activating mutation • Point mutation that constitutively activates map-kinase pathway • Observed in 6-8% of all cancers, including melanoma (60%) colorectal cancer (10%), anaplastic and papillary thyroid carcinomas, low-grade serous ovarian carcinomas • Phase I, sequential dose-escalation study of PLX4032 (oral agent — the most selective BRAF inhibitor to have entered clinical development — N = 55: 49 melanoma,3 thyroid, 1 rectal, 1 ovarian, 1 germ cell) Source: Flaherty K et al. ASCO 2009; Abstract 9000.

  3. ResultsPatients with BRAFV600E Melanoma Treated with PLX4032 > 240 mg BID 100 75 50 25 0 -25 -50 -75 -100 % change from baseline (sum of lesion size) (RECIST cutoff for PR, 30%) Patients (n = 15)* *One patient with M1c had 55% reduction in target lesions, but PD in non-target lesions; died before end C2 (not included above) Source: With permission from Flaherty K et al. ASCO 2009; Abstract 9000.

  4. ResultsPatient with BRAFV600E Melanoma PET Scan at Baseline and Day +15 Treatment at 320 mg BID A patient with response in extensive “intransit” metastases on the leg and more distant skin and lymph node sites Source: With permission from Flaherty K et al. ASCO 2009; Abstract 9000.

  5. Summary and Conclusions • Nearly all AEs were mild and transient, mostly rash, fatigue, photosensitivity but also cutaneous squamous cell cancer following chronic dosing (n = 6) • Responses to PLX4032 with V600E+ melanoma • 9 PRs in 15 patients • Regression of liver, lung and bone metastases • Symptom improvement in many patients • Premature to define PFS, but it appears to be ~6 months, with many patients still on therapy • No evidence of tumor regression in 5 patients with V600E-negative disease • 3 patients with V600E+ papillary thyroid carcinoma: 1 PR, 2 SD • Additional trials planned in melanoma, colorectal cancer and papillary thyroid carcinoma Source: Flaherty K et al. ASCO 2009; Abstract 9000.

More Related